A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management (light parameters) (2022)

Peer-Reviewed Study · Hepburn J, Williams-Lockhart S, Bensadoun RJ, Hanna R · November 8, 2022

Hepburn J et al., 2022-11-08: Pilot study giving the full light prescription used with methylene blue: 660 nm LED, 2928 mW total output, 163 mW/cm2 irradiance, 5-minute sessions, 49 J/cm2 for photodynamic inactivation and 4.9 J/cm2 for photobiomodulation. It is the most completely specified human methylene-blue-plus-red-light protocol found.

The mucosal surfaces were irradiated with 660 nm LED in a continuous emission mode at energy density of 49 J/cm 2 for PDI and 4.9 J/cm 2 for PBM.

Hepburn J et al., 2022-11-08: Pilot study giving the full light prescription used with methylene blue: 660 nm LED, 2928 mW total output, 163 mW/cm2 irradiance, 5-minute sessions, 49 J/cm2 for photodynamic inactivation and 4.9 J/cm2 for photobiomodulation. It is the most completely specified human methylene-blue-plus-red-light protocol found. Study type: open-label pilot, uncontrolled. N=8. Country: Bahamas. Dose: oral MB 1.5-2 mg/kg 12- then 8-hourly (max 200 mg); topical MB solution in nose/mouth for PDI. Light: 660 nm LED, continuous, 2928 mW total power, irradiance 163 mW/cm2, 5 min (300 s), 49 J/cm2 PDI and 4.9 J/cm2 PBM. Comparator: none. Funder: Contigo Foundation. COI: authors declare none; lead author is medical director of Luminnova Health and modified a protocol by Detlef Schikora, with a patent filed. Note: the combined effect of MB plus light is not separated from the oral MB and the natural course of COVID-19 in this design; the paper itself notes 'the MB solution and the light energy alone did not have this effect' with reference to another study. Study type: uncontrolled series.